389TiP Identification of p.G12C KRAS mutation from exhaled breath of patients with lung cancer using FFP2 mask
Background: Young patients with non-small cell lung cancer (NSCLC) represent a distinct biological subgroup, frequently enriched with actionable oncogenic drivers.However, real-world survival data from Latin America are limited.We evaluated survival outcomes and prognostic factors in young versus older patients with NSCLC treated in Peru. Methods:We conducted a retrospective cohort study including patients with histologically confirmed NSCLC treated between 2018 and 2024 at a national reference cancer center.Patients were stratified by age at diagnosis (<45 vs 45 years).Overall survival (OS) was estimated using the Kaplan-Meier method.Multivariable Cox regression was performed adjusting for sex, ECOG performance status, smoking history, clinical stage, histology, molecular alterations and first-line treatment.Results: A total of 317 patients were included; 19.9% were younger than 45 years.The cohort was predominantly female (59.3%), never-smokers (85.5%) and had adenocarcinoma histology (95.6%).Advanced disease (stage III-IV) was present in 94.0% of cases.Actionable molecular alterations were identified in 69.4% of patients, most commonly EGFR mutations (48.3%).Younger patients showed a higher frequency of actionable mutations compared with older patients (70% vs 56%, p=0.038).After a median follow-up of 40.9 months, 92 deaths (29.0%) were recorded.In adjusted analysis, young age was not associated with worse OS (adjusted HR 1.32; 95% CI 0.79-2.21;p=0.29).Former smoking history was the only independent predictor of inferior OS (adjusted HR 2.38; p=0.018).Conclusions: Young age at NSCLC diagnosis was not associated with inferior survival.Despite advanced-stage presentation, younger patients exhibited a high prevalence of actionable oncogenic drivers, supporting routine comprehensive molecular profiling.These results provide robust regional evidence and reinforce the importance of precision oncology in underrepresented populations.
Authors
- Jolanda Palmisani (ORCID: https://orcid.org/0000-0003-2178-5743)
- Alessia Di Gilio
- Fabio Sallustio (ORCID: https://orcid.org/0000-0002-5132-6532)
- Anna Lasorella (ORCID: https://orcid.org/0000-0002-1839-5421)
- Rosanna Lacalamita (ORCID: https://orcid.org/0000-0003-4264-5619)
- Lucio Pastore (ORCID: https://orcid.org/0000-0001-6894-9317)
- M. Mazzola
- Doron Tolomeo (ORCID: https://orcid.org/0000-0002-7187-4237)
- Valentina Pizzillo
- Michele Sansone
- S. Tommasi
- C.T. Storlazzi
- M.R. Nisi
- A. Catino
- D. Galetta
- M. Montrone
- G. de Gennaro
- E.S. Montagna
- A.V. Quarato
Institutions
- Istituto Tumori Bari (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106702
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00